Sign in
TerminatedNo phase

Cytisine Compared to Combination NRT in Relapsed Smokers

Key facts

Who runs it
Ottawa Heart Institute Research Corporation
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
13 people enrolled
Started
14 Mar 2022
Ended
7 Nov 2023
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Cytisine
  • Nicoderm C-Q Transdermal Product
  • Nicorette Lozenge Product
Record updated
8 December 2023
Why it stopped
Feasibility

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patient is enrolled in UOHI's Quit Smoking Program
  • Patient has relapsed to daily smoking ≥10 cigarettes per day within 90 days of discharge from UOHI
  • Patient is currently smoking ≥10 cigarettes per day

Who cannot take part

  • Patient has used NRT, cytisine, varenicline, bupropion or a nicotine-containing vaping device within in the past 15 days
  • Patient is unavailable to come to UOHI for assessments
  • Patient is unable to provide informed consent
  • Patient is unable to comprehend the intervention instructions (in the opinion of qualified investigators)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Cigarette smoking causes cardiovascular disease (CVD) yet many smokers with CVD are unable to quit despite strong desire to do so. Within 90 days of discharge, about 30% of smokers have returned to daily smoking and almost 60% have relapsed by 1 year. Patients with CVD who resume smoking are more likely to experience new events (e.g. heart attack or stroke) or die. New approaches are required. A new type of cessation product is a plant-based medication called Cytisine. Cytisine is taken orally over 25 days and reduces the pleasurable sensations that smokers get from cigarettes and reduces withdrawal symptoms. The primary research question is whether or not it is feasible to conduct a large-scale trial of the effectiveness of this product compared to conventional nicotine replacement therapy in smokers who have failed to quit using conventional methods. To determine feasibility, a pilot study will be conducted of sixty smokers (30 men, 30 women) with CVD who have been treated for smoking cessation but have relapsed within 90 days of discharge. Participants will complete a baseline assessment and will be randomly assigned to either the combination nicotine replacement therapy group (patch plus lozenge) or cytisine group. Participants will be treated for 25 days and then will return to UOHI so adherence to treatment and smoking status can be assessed. Feasibility of the larger trial will be based on: the recruitment rates; adherence to assigned treatments; dropout rates; and differences in 25-day quit rates between groups.

The 2 groups in the trial

  • CytisineTreatment being tested

    Cravv™ (Zpharm, Waterloo) is a natural health product licensed by Health Canada to assist with smoking cessation; each oral capsule contains 1.5mg of cytisine. The dosing is as follows: 6 capsules daily for the first 3 days; 5 capsules daily for days 4-12; 4 capsules daily for days 13-16; 3 capsules daily for days 17-20; and 1-2 capsules daily for days 21-25.

  • NRT+Existing treatment, for comparison

    The Nicoderm® patch plus Nicorette® Lozenge will be provided to participants in the combination NRT group. Participants smoking less than 15 cigarettes per day will be provided with 14 mg patches while those smoking 15 or more cigarettes per day will receive 21 mg patches. Participants will be told to apply a new patch each morning. Participants will be instructed to use the lozenges as needed (up to 15 per day) to overcome nicotine cravings. Lozenges are available in both 2mg and 4mg strengths. For those who are smoking less than 15 cigarettes per day, they will be given the 2mg strength. For those who are smoking 15 or more cigarettes per day, they will receive the 4mg strength.

    Treatment: Nicoderm C-Q Transdermal Product and Nicorette Lozenge Product

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pilot RCT of Cytisine Compared to Combination Nicotine Replacement Therapy to Reduce Cigarette Consumption in Relapsed Smokers
Publications
Record updated
8 December 2023